Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Atezolizumab is named as an intervention in 84 current clinical trials in our USA, China, UK, Ireland and India registers. 35 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Hoffmann-La Roche (24). The most-studied condition is Hepatocellular Carcinoma.

Atezolizumab also has an approved-drug profile on this site (FDA label data): Tecentriq (Atezolizumab) →

Trials by status

Recruiting3542%
Not yet open22%
Active, closed4655%
By invitation11%

Trials by phase

Phase 32530%
Phase 21720%
Phase 11619%
Phase 1/21518%
Phase 2/356%
Observational34%
Not applicable22%
Phase EARLY_PHASE111%

Clinical trials of Atezolizumab

84 trials

Study	Phase	Status	Lead sponsor	Registers
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma NCT07538128 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase EARLY_PHASE1	Recruiting	Huashan Hospital	China
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets NCT05317858 · ClinicalTrials.gov ↗ · Brain Tumor, Non Small Cell Lung Cancer	Phase 3	Recruiting	InSightec	USA
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study NCT05862285 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Recruiting	Hoffmann-La Roche	UK, China
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma NCT06618664 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). NCT06646276 · Extensive-Stage Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer NCT06712355 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma NCT06921785 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy NCT07472517 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 3	Recruiting	Boehringer Ingelheim	Ireland, UK, USA, China
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer NCT07226999 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC)	Phase 2/3	Recruiting	Pfizer	USA, China
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD NCT07285850 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2/3	Recruiting	Eastern Hepatobiliary Surgery Hospital	China
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) NCT04302025 · Non-small Cell Lung Cancer	Phase 2	Recruiting	Genentech, Inc.	USA
PLATFORM Study of Precision Medicine for Rare Tumors NCT04423185 · ClinicalTrials.gov ↗ · Rare Tumor	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB NCT05295212 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Recruiting	Replimune, Inc.	USA
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer NCT07155174 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	AbbVie	USA, China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. NCT07235293 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Kahr Bio Australia Pty Ltd	USA
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma NCT07317414 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer NCT07654400 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005 · Metastatic Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer NCT04802759 · ClinicalTrials.gov ↗ · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	USA
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708 · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Tvardi Therapeutics, Incorporated	USA
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients NCT05703971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	Genprex, Inc.	USA
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) NCT06362252 · ClinicalTrials.gov ↗ · Extensive Stage-small Cell Lung Cancer	Phase 1/2	Recruiting	Daiichi Sankyo	USA
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) NCT07227597 · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors NCT07407933 · ClinicalTrials.gov ↗ · Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	UK, USA
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) NCT04929223 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors NCT05907980 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Chugai Pharmaceutical	USA
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer NCT06179069 · ClinicalTrials.gov ↗ · SCLC	Phase 1	Recruiting	Zai Lab (Shanghai) Co., Ltd.	USA, China
A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma	Phase 1	Recruiting	KaliVir Immunotherapeutics	USA
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice NCT07284121 · Lung Cancer, Hepatocellular Carcinoma	Observational	Recruiting	Hoffmann-La Roche	UK
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT NCT05984511 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus	Not applicable	Recruiting	Third Affiliated Hospital, Sun Yat-Sen University	China
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers NCT07707895 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology	Phase 1/2	Not yet open	Boehringer Ingelheim	UK, USA, China
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC NCT07093762 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Not yet open	Fuzhou General Hospital	China
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study NCT07620574 · ClinicalTrials.gov ↗ · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)	Phase 3	By invitation	Exelixis	USA
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] NCT02486718 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) NCT03148418 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy NCT03755791 · Hepatocellular Carcinoma	Phase 3	Active, closed	Exelixis	Ireland, UK, USA, China
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC NCT04446117 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Prostate Adenocarcinoma	Phase 3	Active, closed	Exelixis	UK, USA
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy NCT04660344 · Muscle-invasive Bladder Cancer	Phase 3	Active, closed	Hoffmann-La Roche	Ireland, UK, USA, China
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma NCT04712643 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	Hoffmann-La Roche	China
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab NCT04770896 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, China
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy NCT04873362 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer NCT05047250 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	China
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer NCT05091567 · Small-Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) NCT05112965 · ClinicalTrials.gov ↗ · Neoplasms	Phase 3	Active, closed	Hoffmann-La Roche	China
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer NCT05425940 · Colorectal Cancer	Phase 3	Active, closed	Exelixis	UK, USA
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC NCT05468489 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 3	Active, closed	Shanghai Henlius Biotech	USA
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) NCT05904886 · Hepatocellular Carcinoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer NCT05141721 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 2/3	Active, closed	Seattle Project Corporation	USA
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) NCT06109272 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Active, closed	AbbVie	USA, China
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · ClinicalTrials.gov ↗ · Neoplasm Metastasis	Phase 2	Active, closed	Genentech, Inc.	UK, USA, China
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors NCT03228667 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma	Phase 2	Active, closed	ImmunityBio, Inc.	USA
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study NCT04589845 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors NCT04931342 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer NCT05009069 · Rectal Neoplasms, Rectal Cancer	Phase 2	Active, closed	Hoffmann-La Roche	China
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer NCT05645692 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC NCT05968326 · Adenocarcinoma, Pancreatic Ductal	Phase 2	Active, closed	Genentech, Inc.	UK, USA
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis NCT06096779 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	Genentech, Inc.	USA
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma NCT03533283 · ClinicalTrials.gov ↗ · Non-Hodgkins Lymphoma	Phase 1/2	Active, closed	Hoffmann-La Roche	UK
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors NCT04440735 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer	Phase 1/2	Active, closed	Kahr Medical	USA
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) NCT04471727 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer, Neuroendocrine Carcinoma	Phase 1/2	Active, closed	Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	USA
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) NCT04524871 · Advanced Liver Cancers	Phase 1/2	Active, closed	Hoffmann-La Roche	USA, China
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab NCT05142696 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 1/2	Active, closed	Novartis Pharmaceuticals	UK, USA, China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors NCT03170960 · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer	Phase 1	Active, closed	Exelixis	UK, USA
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors NCT03845166 · ClinicalTrials.gov ↗ · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma	Phase 1	Active, closed	Exelixis	UK, USA
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) NCT04185883 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation	Phase 1	Active, closed	Amgen	UK, USA
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation NCT04449874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors	Phase 1	Active, closed	Genentech, Inc.	UK, USA
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors NCT05581004 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC	Phase 1	Active, closed	Genentech, Inc.	USA
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC NCT05595460 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage	Phase 1	Active, closed	RayzeBio, Inc.	USA
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. NCT05878691 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Lymphoma	Phase 1	Active, closed	Glenmark Specialty S.A.	USA, India
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT06031441 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors	Phase 1	Active, closed	Genentech, Inc.	UK, USA
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer NCT06077500 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma (SCLC)	Phase 1	Active, closed	Boehringer Ingelheim	USA
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers NCT06496568 · ClinicalTrials.gov ↗ · PIK3CA-Mutated Cancers	Phase 1	Active, closed	Hoffmann-La Roche	USA
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery NCT06117891 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Observational	Active, closed	Bayer	USA, China
Atezolizumab Plus Bevacizumab With HCC and HBV Infection NCT04180072 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular	Not applicable	Active, closed	National Health Research Institutes, Taiwan	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Atezolizumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Atezolizumab on the HPRA medicines list.

Tecentriq 1200 mg concentrate for solution for infusionRoche Registration GmbH · EU/1/17/1220/001
Tecentriq 1875 mg solution for injectionRoche Registration GmbH · EU/1/17/1220/003
Tecentriq 840 mg concentrate for solution for infusionRoche Registration GmbH · EU/1/17/1220/002

All 3 Irish products →

Supply shortages

No entry for Atezolizumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Atezolizumab

83 conditions

Hepatocellular Carcinoma10 Non-Small Cell Lung Cancer6 Colorectal Cancer4 Cancer4 Non Small Cell Lung Cancer4 Small Cell Lung Cancer (SCLC)3 Small Cell Lung Cancer3 Extensive Stage Small Cell Lung Cancer3 Urothelial Carcinoma2 Renal Cell Carcinoma2 Small-Cell Lung Cancer2 Neoplasms2

All 83 conditions

Condition (as registered)	Trials
Hepatocellular Carcinoma	10
Non-Small Cell Lung Cancer	6
Colorectal Cancer	4
Cancer	4
Non Small Cell Lung Cancer	4
Small Cell Lung Cancer (SCLC)	3
Small Cell Lung Cancer	3
Extensive Stage Small Cell Lung Cancer	3
Urothelial Carcinoma	2
Renal Cell Carcinoma	2
Small-Cell Lung Cancer	2
Neoplasms	2
Advanced Solid Tumors	2
Non-small Cell Lung Cancer	2
Extensive-stage Small-cell Lung Cancer	2
Unresectable Hepatocellular Carcinoma	2
Advanced Solid Tumor	2
Small Cell Lung Cancer Extensive Stage	2
Head and Neck Squamous Cell Carcinoma	2
HCC - Hepatocellular Carcinoma	2
Muscle-invasive Bladder Cancer	1
Small Cell Lung Carcinoma	1
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	1
Extensive-Stage Small Cell Lung Cancer	1
Castration-resistant Prostate Cancer	1
Adenocarcinoma, Pancreatic Ductal	1
Metastatic Breast Cancer	1
Lung Cancer, Hepatocellular Carcinoma	1
Non-Hodgkins Lymphoma	1
Neoplasm Malignant	1
Hormone Receptor Positive Breast Carcinoma	1
Metastatic Castration-resistant Prostate Cancer	1
Ovarian Cancer	1
Large Cell Neuroendocrine Lung Carcinoma	1
Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology	1
Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology	1
Neoplasm Metastasis	1
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma	1
Kirsten Rat Sarcoma (KRAS) pG12C Mutation	1
Urothelial Cancer	1
Metastatic Prostate Cancer	1
Prostate Adenocarcinoma	1
Locally Advanced Solid Tumors	1
Recurrent Solid Tumors	1
Metastatic Solid Tumors	1
Solid Tumors	1
Breast Cancer	1
Metastatic Colorectal Cancer	1
Advanced Liver Cancers	1
SCLC,Extensive Stage	1
Small Cell Lung Carcinoma (SCLC)	1
Solid Tumor	1
Biliary Tract Cancer	1
Brain Tumor	1
Lymphoma	1
PIK3CA-Mutated Cancers	1
Large Cell Neuroendocrine Cancer (LCNEC)	1
Neuroendocrine Prostate Cancer (NEPC)	1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)	1
Colorectal Neoplasms	1
Locally Advanced or Metastatic Solid Tumors	1
NSCLC	1
HNSCC	1
Melanoma	1
Neuroendocrine Carcinoma	1
SCLC	1
Renal Cell Carcinoma (RCC)	1
Pancreatic Neuroendocrine Tumors (pNET)	1
Extra-Pancreatic NET (epNET)	1
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	1
Extensive Stage-small Cell Lung Cancer	1
Solid Tumor, Adult	1
Microsatellite Stable Colorectal Cancer	1
Cervical Cancer	1
Rectal Neoplasms	1
Rectal Cancer	1
Advanced Hepatocellular Carcinoma	1
Recurrent Glioblastoma	1
Hepatic Portal Vein Tumor Invasion	1
Tumor Thrombus	1
Carcinoma, Hepatocellular	1
Rare Tumor	1
Solid Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	64	24
Clinical trials in China	43	19
Clinical trials in UK	35	11
Clinical trials in Ireland	4	1
Clinical trials in India	4	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Atezolizumab trials

How many clinical trials are testing Atezolizumab?

84 current trials in our USA, China, UK, Ireland and India registers name Atezolizumab (also registered as RO5541267) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Atezolizumab trials recruiting patients?

Yes. 35 of the 84 trials are recruiting: 24 with sites in USA, 19 with sites in China, 11 with sites in UK, 1 with sites in Ireland and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Atezolizumab clinical trials?

Hoffmann-La Roche (24), Genentech, Inc (7), Exelixis (6) and Boehringer Ingelheim (4), among 43 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Atezolizumab licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Atezolizumab, for example Tecentriq 1200 mg concentrate for solution for infusion (Roche Registration GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Atezolizumab shortage?

Not in the lists we track: Atezolizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Atezolizumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Atezolizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Atezolizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Atezolizumab clinical trials